Rescue of Tumor-Infiltrating Lymphocytes from Activation-Induced Cell Death Enhances the Antitumor CTL Response in CD5-Deficient Mice
暂无分享,去创建一个
F. Mami-Chouaib | K. Benihoud | C. Raman | Y. Lécluse | H. Haouas | K. Franciszkiewicz | Mouna Tabbekh
[1] S. Fiering,et al. A Conserved Enhancer Element Differentially Regulates Developmental Expression of CD5 in B and T Cells , 2010, The Journal of Immunology.
[2] Marion H. Brown,et al. A Ligand for CD5 Is CD5 , 2010, The Journal of Immunology.
[3] M. Nishimura,et al. Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death. , 2009, Cancer research.
[4] J. Yélamos,et al. The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome , 2009, Proceedings of the National Academy of Sciences.
[5] D. Cohen,et al. CD5 plays an inhibitory role in the suppressive function of murine CD4(+) CD25(+) T(reg) cells. , 2008, Immunology letters.
[6] C. Richon,et al. Human CD5 Protects Circulating Tumor Antigen-Specific CTL from Tumor-Mediated Activation-Induced Cell Death1 , 2007, The Journal of Immunology.
[7] S. Barnum,et al. CD5-CK2 Binding/Activation-Deficient Mice Are Resistant to Experimental Autoimmune Encephalomyelitis: Protection Is Associated with Diminished Populations of IL-17-Expressing T Cells in the Central Nervous System1 , 2006, The Journal of Immunology.
[8] P. Opolon,et al. Expression of non‐signaling membrane‐anchored death receptors protects murine livers in different models of hepatitis , 2006, Hepatology.
[9] W. Tan,et al. FASL –844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer , 2005, The Journal of experimental medicine.
[10] S. Anderton,et al. Fas‐mediated death and sensory adaptation limit the pathogenic potential of autoreactive T cells after strong antigenic stimulation , 2005, Journal of leukocyte biology.
[11] Robert C. Rose,et al. Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor1 , 2005, The Journal of Immunology.
[12] P. Opolon,et al. In Situ Sensory Adaptation of Tumor-Infiltrating T Lymphocytes to Peptide-MHC Levels Elicits Strong Antitumor Reactivity1 , 2005, The Journal of Immunology.
[13] S. Rosenberg,et al. Survival, Persistence, and Progressive Differentiation of Adoptively Transferred Tumor-Reactive T Cells Associated with Tumor Regression , 2005, Journal of immunotherapy.
[14] S. Rosenberg,et al. Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred , 2022 .
[15] K. Hiraoka,et al. Enhanced Tumor-Specific Long-Term Immunity of Hemaggluttinating Virus of Japan-Mediated Dendritic Cell-Tumor Fused Cell Vaccination by Coadministration with CpG Oligodeoxynucleotides1 , 2004, The Journal of Immunology.
[16] S. Barnum,et al. Cutting Edge: Critical Role for CD5 in Experimental Autoimmune Encephalomyelitis: Inhibition of Engagement Reverses Disease in Mice1 , 2004, The Journal of Immunology.
[17] M. Nussenzweig,et al. Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. , 2004, Immunity.
[18] K. Hiraoka,et al. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. , 2004, Journal of immunology.
[19] D. Kioussis,et al. Chronic Exposure to Low Levels of Antigen in the Periphery Causes Reversible Functional Impairment Correlating with Changes in CD5 Levels in Monoclonal CD8 T Cells , 2003, The Journal of Immunology.
[20] A. Trautmann,et al. CD5 Inhibits Signaling at the Immunological Synapse Without Impairing Its Formation 1 , 2003, The Journal of Immunology.
[21] B. Stockinger,et al. Involvement of Avidity for Major Histocompatibility Complex in Homeostasis of Naive and Memory T Cells , 2003, The Journal of experimental medicine.
[22] F. Sánchez‐Madrid,et al. The Accessory Molecules CD5 and CD6 Associate on the Membrane of Lymphoid T Cells* , 2003, The Journal of Biological Chemistry.
[23] F. Mami-Chouaib,et al. Tumor-Infiltrating CD4+ T Lymphocytes Express APO2 Ligand (APO2L)/TRAIL upon Specific Stimulation with Autologous Lung Carcinoma Cells: Role of IFN-α on APO2L/TRAIL Expression and -Mediated Cytotoxicity1 , 2002, The Journal of Immunology.
[24] A. Singer,et al. CD5‐mediated inhibition of TCR signaling during intrathymic selection and development does not require the CD5 extracellular domain , 2002, European journal of immunology.
[25] Georges Bismuth,et al. CD5-Negative Regulation of B Cell Receptor Signaling Pathways Originates from Tyrosine Residue Y429 Outside an Immunoreceptor Tyrosine-Based Inhibitory Motif1 , 2002, The Journal of Immunology.
[26] R. Budd,et al. Activation-induced cell death. , 2001, Current opinion in immunology.
[27] C. Park,et al. Fine Tuning of TCR Signaling by CD5 , 2001, The Journal of Immunology.
[28] A. Tarakhovsky,et al. Negative regulation of CD4 lineage development and responses by CD5. , 1999, Journal of immunology.
[29] M. Bowen,et al. Interaction of recombinant and natural soluble CD5 forms with an alternative cell surface ligand , 1999, European journal of immunology.
[30] S. Rosenberg,et al. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. , 1999, Journal of immunology.
[31] R. Siegel,et al. Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. , 1999, Annual review of immunology.
[32] A. Grinberg,et al. CD5 Expression Is Developmentally Regulated By T Cell Receptor (TCR) Signals and TCR Avidity , 1998, The Journal of experimental medicine.
[33] A. Aruffo,et al. A role for CD5 in cognate interactions between T cells and B cells, and identification of a novel ligand for CD5. , 1998, International immunology.
[34] I. Stamenkovic,et al. Identification of a novel inducible cell-surface ligand of CD5 on activated lymphocytes , 1996, The Journal of experimental medicine.
[35] K. Rajewsky,et al. A role for CD5 in TCR-mediated signal transduction and thymocyte selection. , 1995, Science.
[36] P. Fink,et al. Positive selection of thymocytes. , 1995, Annual review of immunology.
[37] K. Rajewsky,et al. Lymphocyte populations and immune responses in CD5‐deficient mice , 1994, European journal of immunology.
[38] M. Krieger,et al. The SRCR superfamily: a family reminiscent of the Ig superfamily. , 1994, Trends in biochemical sciences.
[39] A. Williams,et al. Molecular associations between the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and CD5. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[40] H. Velde,et al. The B-cell surface protein CD72/Lyb-2 is the ligand for CDS , 1991, Nature.
[41] M. Freeman,et al. Type I macrophage scavenger receptor contains α-helical and collagen-like coiled coils , 1990, Nature.
[42] M. Freeman,et al. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. , 1990, Nature.
[43] J. Strominger,et al. Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1/Leu-1 , 1986, Nature.